Clinical trials: Castrate-resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
This study is designed to evaluate the efficacy of pamiparib in participants with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency…
- Trial name
- NCT03712930
- Testing
- Pamiparib
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- BeiGene
Prostatic Neoplasms
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
- Trial name
- NCT00448409
- Testing
- TroVax, GM-CSF
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Disease, Radiation Nephropathy
Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
The goal of this observational study is to determine the impact of 177Lutetium-Prostate Specific Membrane Antigen (PSMA) Radioligand Therapy (177Lu-PSMA-RLT) on kidney function over time.
- Conditions
- Kidney Disease, Radiation Nephropathy, Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Trial name
- KiRi (NCT06720532)
- Testing
- characterization of renal function., Handgrip strength test, Questionaires
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Hannah Schaefer
Oligometastatic Disease, Prostatic Cancer, Castration-Resistant
Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer
The purpose of this randomized trial is to investigate the efficacy and toxicity of percutaneous high-dose radiotherapy in patients with oligometastases of hormone refractory prostate cancer.
- Trial name
- OLI-CR-P (NCT04141709)
- Testing
- local ablative radiotherapy
- Where
- 4 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Technische Universität Dresden
Pharmacokinetics of MDV3100, Castration Resistant Prostate Cancer (CRPC)
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19…
- Trial name
- NCT01911728
- Testing
- MDV3100, Pioglitazone, Warfarin
- Where
- 2 sites in South Africa
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Europe B.V.
Metastatic Castration-Resistant Prostate Cancer, mCRPC
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or…
- Trial name
- NCT07850921
- Testing
- REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
- Volunteers
- 192 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Cancer of Prostate, Cancer of the Prostate
Sipuleucel-T Manufacturing Demonstration Study
To demonstrate that sipuleucel-T can be successfully manufactured for subjects with metastatic castrate resistant prostate cancer (mCRPC) at a European manufacturing facility.
- Conditions
- Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic
- Trial name
- NCT01477749
- Testing
- sipuleucel-T
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 47 people
- Sponsor
- Dendreon
Prostate Cancer
Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer
This pilot study is designed to determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in older men with hormone refractory prostate cancer.
- Trial name
- NCT00215709
- Testing
- docetaxel
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Geriatric Oncology Consortium
Prostate Cancer
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00046826
- Testing
- docetaxel, estramustine phosphate sodium, thalidomide
- Where
- 2 sites in United States
- Sponsor
- Nuvance Health
Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate
Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic…
- Trial name
- NCT04586543
- Testing
- Selegiline, Docetaxel
- Where
- Hungary
- Volunteers
- 110 people
- Sponsor
- László Mangel
Metastatic Castration-resistant Prostate Cancer
Post Marketing Study on Pluvicto in Korea
Post marketing study on Pluvicto in Korea
- Trial name
- NCT06514521
- Testing
- Lutetium vipivotide tetraxetan
- Where
- 12 sites in South Korea
- Volunteers
- 278 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms, Castration-Resistant
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic…
- Trial name
- NCT05169684
- Testing
- BMS-986218, Docetaxel, Nivolumab
- Where
- 31 sites in United States, France and 1 more
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.
- Trial name
- NCT02758132
- Testing
- Denosumab, Enzalutamide, Abiraterone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Hawaii
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Microsatellite Instability
- Trial name
- NCT02966587
- Testing
- Durvalumab, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Washington
Prostate Cancer
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor…
- Trial name
- NCT07567521
- Testing
- Radiopharmaceuticals
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- C Ray Therapeutics
Hormone Refractory Prostate Cancer
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
This is a Phase II open-label study evaluating the preliminary efficacy and safety of bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory Prostate Cancer.
- Trial name
- PROACT (NCT01215799)
- Testing
- Bafetinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CytRx
Prostate Cancer
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
Evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer.
- Trial name
- NCT00193232
- Testing
- Docetaxel, Bortezomib
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
- Trial name
- NCT05588609
- Testing
- Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Partner Therapeutics, Inc.
Prostate Adenocarcinoma
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
This study is designed to evaluate the initial safety and effectiveness of an investigational drug, niraparib, given to patients who have recently received platinum-based chemotherapy for the treatment of prostate cancer.
- Trial name
- NCT04288687
- Testing
- Niraparib Pill
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.